Theravance Biopharma, Inc..
TBPH.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective medicines. The company's research and development efforts are centered on addressing unmet needs in respiratory disease and other areas of high unmet me...Show More
Better Health for All
-30
Theravance Biopharma's core purpose is to create transformational medicines that improve the lives of patients suffering from serious illnesses, focusing on localized medicines to maximize patient benefit and minimize risk.
1
Its product portfolio, including FDA-approved YUPELRI for COPD and Ampreloxetine in Phase 3 development for symptomatic neurogenic orthostatic hypotension in Multiple System Atrophy, addresses significant unmet medical needs.
2
The company does not generate revenue from products with established negative health impacts. Clinical trials for YUPELRI and Ampreloxetine reported generally good safety profiles, with adverse events being low, mild, or moderate, and no deaths related to Ampreloxetine.
3
For YUPELRI, approximately 90% of commercially insured patients pay $0 out-of-pocket, and Medicare Part B covers 80% of the cost, with a Patient Assistance Program available for uninsured patients.
4
Ampreloxetine has received Orphan Drug Designation from the FDA.
5
The company's Form 10-K contains a "Risk Factors" section detailing potential risks and uncertainties, and YUPELRI's website includes warnings about potential side effects.
6
The company discontinued its research activities in February 2023, prioritizing R&D resources toward the ampreloxetine Phase 3 study and the YUPELRI Phase 4 study.
7
Royalty Pharma agreed to invest up to $40.0 million to advance ampreloxetine development.
8
The company has a Diversity, Equity & Inclusion Council and Women’s Leadership Network, and strives to eliminate discrimination.
9
It invests in employee learning and development, offers a competitive total rewards package, and provides an Employee Assistance Program.
10
The company offers a corporate wellness program with health and wellness initiatives.
11
It is subject to laws and regulations addressing privacy and data security.
12
During the COVID-19 pandemic, the company focused on employee wellness and safety, policy updates, and ongoing communication.
13
The company has settled litigation with several generic companies, granting them royalty-free licenses to market generic versions of YUPELRI in the US on or after April 23, 2039, while the last to expire patent is October 23, 2039.
14
The company conducts clinical trials to assess safety and efficacy and is responsible for ensuring they are conducted in accordance with good clinical practices.
15
Fair Money & Economic Opportunity
0
No evidence available to assess Theravance Biopharma, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No specific, concrete data points for Theravance Biopharma, Inc. (TBPH.US) were found across the provided articles for any of the 'Fair Pay & Worker Respect' KPIs. is a generic post.
1
pertains to GSK's operations, not TBPH.US.
2
discusses general market trends and S&P 500 companies without providing specific data for TBPH.US.
3
Fair Trade & Ethical Sourcing
0
No specific quantitative evidence was found in the provided articles for any of the Fair Trade & Ethical Sourcing KPIs. While some articles mention the existence of a Supplier Code of Conduct, expectations for suppliers regarding child labor and conflict minerals, or the company's Code of Business Conduct, these are policy statements or general expectations, not concrete, measurable data points that can be mapped to the rubric's quantitative thresholds for fair trade certification share, audit frequency, forced/child labor incidents, traceability coverage, remediation speed, ethical clause coverage, materials risk index, or supplier diversity spend.
1
Honest & Fair Business
0
No evidence was found in the provided articles to assess Theravance Biopharma, Inc. against any of the 'Honest & Fair Business' KPIs.
1
The articles explicitly state that no data relevant to the company's ethical or ESG performance, regulatory actions, fines, or transparency is present.
2
Kind to Animals
-20
The company is subject to various laws and regulations regarding the experimental use of animals in drug development.
1
All animal experiments are performed under protocols approved by the Institutional Animal Care and Use Committee and in strict accordance with recommendations from the Guide for the Care and Use of Laboratory Animals.
2
The company's policy prohibits discretionary testing, but legal mandates still override alternatives.
No War, No Weapons
0
No evidence available to assess Theravance Biopharma, Inc. on No War, No Weapons.
Planet-Friendly Business
-30
The company has no specific regulatory actions, violations, fines, or compliance issues mentioned across multiple financial and ESG summaries.
1
Respect for Cultures & Communities
0
No specific, concrete data points or evidence related to Theravance Biopharma, Inc.'s respect for cultures and communities were found in the provided articles.
1
explicitly states no relevant data, and is a 404 error page.
2
Therefore, no KPIs could be scored against the rubric.
Safe & Smart Tech
0
No evidence available to assess Theravance Biopharma, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
The provided articles, which are primarily financial and regulatory updates, do not contain specific, quantifiable information regarding the company's waste diversion rates, product recyclability, packaging sustainability, use of recycled content, single-use plastic reduction, take-back programs, or circular design principles.
1
There is also no data on waste reduction initiatives, hazardous waste management performance, product durability, repairability, waste audit frequency, zero waste certifications, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education programs.
2
While the company acknowledges the use of potentially hazardous substances and adherence to relevant laws, no specific performance data or initiatives related to hazardous waste management are provided.
3